Exane Derivatives Atreca, Inc. Transaction History

Exane Derivatives

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 30, 2021	SELL	$13.0 - $19.34 $104,884 - $156,035	-8,068 Closed	0 $0
Q3 2020 Oct 06, 2020	BUY	$12.67 - $23.19 $48,120 - $88,075	3,798 Added 88.95%	8,068 $112,000
Q1 2020 Apr 17, 2020	BUY	$11.4 - $27.28 $48,678 - $116,485	4,270 New	4,270 $70,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

Stay updated on Exane Derivatives with notifications on news.